Patents by Inventor Jo-Anne Hongo

Jo-Anne Hongo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140106374
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 17, 2014
    Applicant: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Patent number: 8617559
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 31, 2013
    Assignee: Genetech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Publication number: 20130336885
    Abstract: The invention provides anti-LgR5 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 29, 2013
    Publication date: December 19, 2013
    Applicant: GENENTECH INC.
    Inventors: Jo-Anne Hongo, Weiguang Mao, Paul Polakis, Andrew Polson, Rajesh Vij, Yan Wu, Wei-Ching Liang
  • Patent number: 8563695
    Abstract: Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of ?2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: October 22, 2013
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Jing Li, Victoria Smith
  • Publication number: 20130266973
    Abstract: The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Inventors: Jo-Anne Hongo, Yanhong Li, Luna Liu, John Lowe, Mauricio Maia, Rajesh Vij, Terence Wong, Keyang XU
  • Patent number: 8466260
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: June 18, 2013
    Assignee: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Patent number: 8398976
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: March 19, 2013
    Assignee: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Patent number: 8362213
    Abstract: Anti-FcRH5 antibodies and immunoconjugates thereof are provided. Methods of using anti-FcRH5 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: January 29, 2013
    Assignee: Genentech, Inc.
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Publication number: 20120045443
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Application
    Filed: August 5, 2011
    Publication date: February 23, 2012
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
  • Publication number: 20110200602
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 18, 2011
    Applicant: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Publication number: 20110182886
    Abstract: Compositions and methods are provided for the classification, diagnosis, treatment, and prevention of tumors characterized by loss of REST function, expression of ?2, and/or activation of Notch. Further compositions and methods are provided for modulation of cellular processes such as EMT, cell migration, and apoptosis.
    Type: Application
    Filed: November 18, 2008
    Publication date: July 28, 2011
    Inventors: Jo-Anne Hongo, Jing Li, Victoria Smith
  • Patent number: 7982015
    Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: July 19, 2011
    Assignee: Genentech, Inc.
    Inventors: Fred de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne Hongo, Victoria Smith
  • Publication number: 20110171125
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 14, 2011
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Patent number: 7858330
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen D. Frantz, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Publication number: 20100260748
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 14, 2010
    Inventors: Kristi Elkins, Andrew Polson, Allen Ebens, Camelia Adams, Bing Zheng, Jagath R. Junutula, Jo-Anne Hongo, Yan Wu
  • Publication number: 20100203041
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: March 16, 2007
    Publication date: August 12, 2010
    Applicant: Genentech , Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Publication number: 20100003261
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention andior treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Application
    Filed: June 4, 2009
    Publication date: January 7, 2010
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
  • Patent number: 7615383
    Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: November 10, 2009
    Assignee: Genentech, Inc.
    Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
  • Publication number: 20080138345
    Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
    Type: Application
    Filed: May 2, 2005
    Publication date: June 12, 2008
    Inventors: Fred de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne Hongo, Victoria Smith
  • Patent number: 7384632
    Abstract: The invention concerns agonist anti-trkC monoclonal antoibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: June 10, 2008
    Assignee: Genentech, Inc.
    Inventors: Brigitte Devaux, David L. Shelton, Jo-Anne Hongo, Leonard G. Presta